abs427.txt	ras	genes	(hras		kras		and	nras)	comprise	the	most	frequently	mutated	oncogenefamily	in	human	cancer		with	the	highest	ras	mutation	frequencies	seen	with	thetop	three	causes	of	cancer	deaths	in	the	united	states	(lung		colorectal		andpancreatic	cancer)		the	development	of	anti-ras	therapies	is	a	major	priority	forcancer	research		despite	more	than	three	decades	of	intense	effort		no	effectiveras	inhibitors	have	yet	to	reach	the	cancer	patient		with	bitter	lessons	learnedfrom	past	failures	and	with	new	ideas	and	strategies		there	is	renewed	hope	thatundruggable	ras	may	finally	be	conquered		with	the	kras	isoform	mutated	in	84%	ofall	ras-mutant	cancers		we	focus	on	kras		with	a	near	100%	kras	mutationfrequency		pancreatic	ductal	adenocarcinoma	(pdac)	is	considered	the	mostras-addicted	of	all	cancers		we	review	the	role	of	kras	as	a	driver	andtherapeutic	target	in	pdac	
